Valvular & structural heart disease
Randomized comparison of transcatheter aortic valve implantation (TAVI) valves: The Compare-TAVI trial
Study context
- Population
- Patients scheduled for TAVI, preferably all comersplanned 1062
- Planned comparison
- Sapien 3/Sapien 3 Ultra Transcatheter Heart Valve (THV) vs Myval/Myval Octacor THV
- Primary endpoint
- Composite safety and efficacy endpoint: death, stroke, moderate-severe aortic regurgitation, moderate-severe valve deterioration
- Follow-up
- 1 year
Methodological detailsdesign and rationale, non-inferiority, 1:1 randomisation, consecutive cohorts, Enrollment finalized in cohort B, Follow-up until withdrawal of consent, death or 10 years; secondary endpoints at 30 days, 1, 3, 5 and 10 years
- Design and rationale
- Non-inferiority
- 1:1 randomisation
- Consecutive cohorts
- Enrollment finalized in cohort B
- Follow-up until withdrawal of consent, death or 10 years; secondary endpoints at 30 days, 1, 3, 5 and 10 years
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Randomized comparison of TAVI valves: The Compare-TAVI trial. Am Heart J. Published 9 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →